ENGN vs. BCSF, CVII, TRIN, AACT, CION, AIRJ, NETD, RRAC, IPXX, and CDRO
Should you be buying enGene stock or one of its competitors? The main competitors of enGene include Bain Capital Specialty Finance (BCSF), Churchill Capital Corp VII (CVII), Trinity Capital (TRIN), Ares Acquisition Co. II (AACT), CION Investment (CION), Montana Technologies (AIRJ), Nabors Energy Transition Corp. II (NETD), Rigel Resource Acquisition (RRAC), Inflection Point Acquisition Corp. II (IPXX), and Codere Online Luxembourg (CDRO). These companies are all part of the "holding & other investment offices" industry.
Bain Capital Specialty Finance (NYSE:BCSF) and enGene (NASDAQ:ENGN) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, community ranking, analyst recommendations, valuation and institutional ownership.
Bain Capital Specialty Finance has higher revenue and earnings than enGene.
64.2% of enGene shares are owned by institutional investors. 0.6% of Bain Capital Specialty Finance shares are owned by insiders. Comparatively, 13.7% of enGene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Bain Capital Specialty Finance and Bain Capital Specialty Finance both had 1 articles in the media. Bain Capital Specialty Finance's average media sentiment score of 1.91 beat enGene's score of 0.30 indicating that enGene is being referred to more favorably in the news media.
Bain Capital Specialty Finance received 50 more outperform votes than enGene when rated by MarketBeat users. However, 100.00% of users gave enGene an outperform vote while only 43.18% of users gave Bain Capital Specialty Finance an outperform vote.
Bain Capital Specialty Finance has a net margin of 43.42% compared to Bain Capital Specialty Finance's net margin of 0.00%. enGene's return on equity of 12.64% beat Bain Capital Specialty Finance's return on equity.
Bain Capital Specialty Finance presently has a consensus price target of $16.33, suggesting a potential downside of 1.72%. enGene has a consensus price target of $34.40, suggesting a potential upside of 320.02%. Given Bain Capital Specialty Finance's stronger consensus rating and higher possible upside, analysts clearly believe enGene is more favorable than Bain Capital Specialty Finance.
Bain Capital Specialty Finance has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, enGene has a beta of -0.64, indicating that its share price is 164% less volatile than the S&P 500.
Summary
Bain Capital Specialty Finance and enGene tied by winning 7 of the 14 factors compared between the two stocks.
Get enGene News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
